CAPR Quote, Financials, Valuation and Earnings

Arcturus Therapeutics Holdings has a net margin of -63.94% compared to Capricor Therapeutics's net margin of -142.88%. Capricor Therapeutics's return on equity of -75.99% beat Arcturus Therapeutics Holdings's return on equity of -31.04%.

Capricor Therapeutics has a consensus price target of $43.71, signalling upside risk potential of 224.29%. On the other hand Arcturus Therapeutics Holdings has an analysts' consensus of $73.10 which suggests that it could grow by 472.44%. Given that Arcturus Therapeutics Holdings has higher upside potential than Capricor Therapeutics, analysts believe Arcturus Therapeutics Holdings is more attractive than Capricor Therapeutics.

Capricor Therapeutics has a beta of 4.096, which suggesting that the stock is 309.586% more volatile than S&P 500. In comparison Arcturus Therapeutics Holdings has a beta of 2.962, suggesting its more volatile than the S&P 500 by 196.207%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcturus Therapeutics Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Arcturus Therapeutics Holdings pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are smaller than Arcturus Therapeutics Holdings quarterly revenues of $21M. Capricor Therapeutics's net income of -$7.1M is higher than Arcturus Therapeutics Holdings's net income of -$30M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Arcturus Therapeutics Holdings's PE ratio is 8.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 21.31x versus 2.49x for Arcturus Therapeutics Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals has a net margin of -63.94% compared to Capricor Therapeutics's net margin of --. Capricor Therapeutics's return on equity of -75.99% beat Armata Pharmaceuticals's return on equity of --.

Capricor Therapeutics has a consensus price target of $43.71, signalling upside risk potential of 224.29%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 316.67%. Given that Armata Pharmaceuticals has higher upside potential than Capricor Therapeutics, analysts believe Armata Pharmaceuticals is more attractive than Capricor Therapeutics.

Capricor Therapeutics has a beta of 4.096, which suggesting that the stock is 309.586% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.295%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Capricor Therapeutics's net income of -$7.1M is lower than Armata Pharmaceuticals's net income of $2.6M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 21.31x versus 608.95x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings has a net margin of -63.94% compared to Capricor Therapeutics's net margin of 0.18%. Capricor Therapeutics's return on equity of -75.99% beat Envista Holdings's return on equity of -32.33%.

Capricor Therapeutics has a consensus price target of $43.71, signalling upside risk potential of 224.29%. On the other hand Envista Holdings has an analysts' consensus of $21.33 which suggests that it could grow by 22.25%. Given that Capricor Therapeutics has higher upside potential than Envista Holdings, analysts believe Capricor Therapeutics is more attractive than Envista Holdings.

Capricor Therapeutics has a beta of 4.096, which suggesting that the stock is 309.586% more volatile than S&P 500. In comparison Envista Holdings has a beta of 1.326, suggesting its more volatile than the S&P 500 by 32.59%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are smaller than Envista Holdings quarterly revenues of $652.9M. Capricor Therapeutics's net income of -$7.1M is lower than Envista Holdings's net income of $1.2M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 21.31x versus 1.20x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -63.94% compared to Capricor Therapeutics's net margin of 35.65%. Capricor Therapeutics's return on equity of -75.99% beat Protalix BioTherapeutics's return on equity of 8.75%.

Capricor Therapeutics has a consensus price target of $43.71, signalling upside risk potential of 224.29%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 473.12%. Given that Protalix BioTherapeutics has higher upside potential than Capricor Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Capricor Therapeutics.

Capricor Therapeutics has a beta of 4.096, which suggesting that the stock is 309.586% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.611%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Capricor Therapeutics's net income of -$7.1M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 84.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 21.31x versus 3.93x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.